DANBURY, Conn., Oct. 26, 2007 (PRIME NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) announced today that it has completed patient enrollment in its Phase IIa clinical trial of nalbuphine hydrochloride extended release tablet formulation (nalbuphine ER), a product the Company is developing for the treatment of chronic pain.
